1. Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial. Issue 3 (11th May 2021) Authors: Rosmarin, D.; Smith, S.; Shrom, D.; Burge, R.; See, K.; McKean‐Matthews, M.; Ridenour, T.; Lin, C.‐Y.; Gorelick, J. Journal: Skin health and disease Issue: Volume 1:Issue 3(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment. (12th November 2020) Authors: Reddy, R.; Pannu, S.; Fiumara, K.; Kahn, J.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment. (1st March 2021) Authors: Reddy, R.; Pannu, S.; Fiumara, K.; Kahn, J.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hailey–Hailey disease treated with dupilumab: a case series. (1st September 2021) Authors: Alzahrani, N.; Grossman‐Kranseler, J.; Swali, R.; Fiumara, K.; Zancanaro, P.; Tyring, S.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Hailey–Hailey disease treated with dupilumab: a case series. (5th July 2021) Authors: Alzahrani, N.; Grossman‐Kranseler, J.; Swali, R.; Fiumara, K.; Zancanaro, P.; Tyring, S.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. (1st July 2019) Authors: Blauvelt, A.; Rosmarin, D.; Bieber, T.; Simpson, E.L.; Bagel, J.; Worm, M.; Deleuran, M.; Katoh, N.; Kawashima, M.; Shumel, B.; Chen, Z.; Rossi, A.B.; Hultsch, T.; Ardeleanu, M. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. (22nd March 2019) Authors: Blauvelt, A.; Rosmarin, D.; Bieber, T.; Simpson, E.L.; Bagel, J.; Worm, M.; Deleuran, M.; Katoh, N.; Kawashima, M.; Shumel, B.; Chen, Z.; Rossi, A.B.; Hultsch, T.; Ardeleanu, M. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa. (12th May 2019) Authors: Prussick, L.; Rothstein, B.; Joshipura, D.; Saraiya, A.; Turkowski, Y.; Abdat, R.; Alomran, A.; Zancanaro, P.; Kachuk, C.; Dumont, N.; Gottlieb, A.B.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 181:Number 3(2019) Page Start: 609 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa. (1st September 2019) Authors: Prussick, L.; Rothstein, B.; Joshipura, D.; Saraiya, A.; Turkowski, Y.; Abdat, R.; Alomran, A.; Zancanaro, P.; Kachuk, C.; Dumont, N.; Gottlieb, A.B.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 181:Number 3(2019) Page Start: 609 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. (1st January 2019) Authors: Gordon, S.C.; Abudu, M.; Zancanaro, P.; Ko, J.M.; Rosmarin, D. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 4(2019) Page Start: e156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗